Showing results (41-50 of 223) with videos related to
Sort By:
Pageof 23
Current Medical Research and Opinion|November 8, 2019
Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims studyMaria Cecilia Vieira, Devon Conway, Gina Mavrikis Cox, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 17, 2017
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple SclerosisBurhan Z Chaudhry, Jeffrey A Cohen, Devon S ConwayMultiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2016
Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease courseDevon S Conway, Nicolas R Thompson, Jeffrey A CohenMultiple Sclerosis and Related Disorders|September 21, 2016
Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomesDevon S Conway, Nicolas R Thompson, Jeffrey A CohenMultiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2007
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controlsMyla D Goldman, Ruth Ann Marrie, Jeffrey A CohenNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|June 28, 2017
Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future DirectionsAndrew L Smith, Jeffrey A Cohen, Le H HuaExpert Opinion on Drug Safety|November 2, 2016
Safety of monoclonal antibodies for the treatment of multiple sclerosisMarisa P McGinley, Brandon P Moss, Jeffrey A CohenHandbook of Clinical Neurology|August 7, 2024
Ongoing randomized clinical trials on HSCT in multiple sclerosisMatilde Inglese, Jeffrey A Cohen, Basil Sharrack, et al.Neurologic Clinics|November 18, 2023
Autologous Hematopoietic Stem Cell Transplantation to Treat Multiple SclerosisLindsay A Ross, Lisa M Stropp, Jeffrey A CohenNeurodegenerative Disease Management|January 30, 2026
Real-world experience of ozanimod in adults with multiple sclerosisJessica Cooperrider, Jeffrey Lambe, Michelle Chu, et al.Pageof 23